ketorolac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anti-inflammatory agents, ibufenac derivatives	1529	74103-06-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketorolac ketorolac tromethamine ketorolac trometamol trometamol ketorolac (+/-)-Ketorolac keromin	A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity. Molecular weight: 255.27 Formula: C15H13NO3 CLOGP: 1.62 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 59.30 ALOGS: -2.70 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ketorolac
ketorolac tromethamine
ketorolac trometamol
trometamol ketorolac
(+/-)-Ketorolac
keromin

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Molecular weight: 255.27
Formula: C15H13NO3
CLOGP: 1.62
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 59.30
ALOGS: -2.70
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
30	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	58 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	9.79 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.35 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 30, 1989	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	482.93	13.65	452	13073	250558	50341041
Punctate keratitis	88.07	13.65	22	13503	535	50591064
Corneal epithelium defect	77.57	13.65	18	13507	317	50591282
Spinal epidural haematoma	75.56	13.65	22	13503	967	50590632
Skin papilloma	69.52	13.65	30	13495	4199	50587400
Tendon disorder	62.92	13.65	30	13495	5292	50586307
Eye irritation	57.93	13.65	43	13482	17097	50574502
Renal infarct	52.62	13.65	18	13507	1342	50590257
Eye pain	51.84	13.65	50	13475	28399	50563200
Anterior chamber cell	51.43	13.65	14	13511	480	50591119
Injury	50.81	13.65	64	13461	48861	50542738
Retinal pigment epitheliopathy	48.69	13.65	11	13514	171	50591428
Corneal oedema	48.42	13.65	17	13508	1370	50590229
Aspirin-exacerbated respiratory disease	47.68	13.65	15	13510	859	50590740
Concussion	44.82	13.65	27	13498	7601	50583998
Ulcerative keratitis	43.16	13.65	18	13507	2315	50589284
Treatment failure	42.09	13.65	105	13420	137532	50454067
Purpura fulminans	41.72	13.65	8	13517	52	50591547
Meniscus injury	36.23	13.65	22	13503	6280	50585319
Uterine perforation	35.87	13.65	22	13503	6393	50585206
Corneal disorder	35.06	13.65	14	13511	1612	50589987
Anaphylactic reaction	34.38	13.65	56	13469	53999	50537600
Migraine	33.80	13.65	67	13458	75213	50516386
Respiratory tract infection viral	33.61	13.65	14	13511	1795	50589804
Musculoskeletal disorder	32.56	13.65	31	13494	17318	50574281
Emotional distress	32.17	13.65	39	13486	28624	50562975
Ocular hyperaemia	28.49	13.65	31	13494	20261	50571338
Visual acuity reduced	26.95	13.65	30	13495	20109	50571490
Sleep disorder	26.94	13.65	52	13473	57231	50534368
Vision blurred	26.15	13.65	62	13463	78585	50513014
Asymptomatic bacteriuria	25.23	13.65	7	13518	258	50591341
Myelomalacia	25.16	13.65	5	13520	40	50591559
Post-traumatic stress disorder	24.68	13.65	15	13510	4288	50587311
Systemic lupus erythematosus	24.66	13.65	4	13521	140618	50450981
Foreign body sensation in eyes	23.85	13.65	11	13514	1800	50589799
Tracheal deviation	23.81	13.65	5	13520	54	50591545
Renal ischaemia	23.68	13.65	8	13517	574	50591025
Intraocular pressure increased	23.63	13.65	16	13509	5500	50586099
Condition aggravated	21.89	13.65	145	13380	296913	50294686
Fibrosis	21.33	13.65	13	13512	3734	50587865
Corneal thinning	20.85	13.65	5	13520	102	50591497
Phrenic nerve paralysis	20.76	13.65	5	13520	104	50591495
Corneal abrasion	20.61	13.65	8	13517	854	50590745
Dystonia	19.93	13.65	20	13505	11906	50579693
Immune thrombocytopenia	18.63	13.65	17	13508	9000	50582599
Torsade de pointes	18.24	13.65	19	13506	11816	50579783
Persistent corneal epithelial defect	18.07	13.65	3	13522	7	50591592
Corneal perforation	17.18	13.65	6	13519	476	50591123
Renal papillary necrosis	17.03	13.65	5	13520	226	50591373
Abdominal pain	16.60	13.65	114	13411	236114	50355485
Alopecia	16.48	13.65	25	13500	245022	50346577
Spinal cord compression	16.47	13.65	11	13514	3698	50587901
Anxiety	16.42	13.65	92	13433	177514	50414085
Atrophy	16.24	13.65	8	13517	1515	50590084
Colitis ischaemic	16.02	13.65	16	13509	9467	50582132
Eye pruritus	15.62	13.65	18	13507	12516	50579083
Sinusitis	15.54	13.65	88	13437	170470	50421129
Depression	15.50	13.65	86	13439	165337	50426262
Fascial infection	15.45	13.65	3	13522	21	50591578
Corneal opacity	15.39	13.65	6	13519	648	50590951
Corneal dystrophy	15.34	13.65	5	13520	321	50591278
Opisthotonus	15.29	13.65	5	13520	324	50591275
Paraplegia	15.23	13.65	9	13516	2445	50589154
Hand deformity	15.19	13.65	4	13521	100195	50491404
Small intestinal obstruction	15.07	13.65	20	13505	16048	50575551
Hypothyroidism	14.86	13.65	30	13495	34095	50557504
Photophobia	14.69	13.65	19	13506	14868	50576731
Intervertebral discitis	14.57	13.65	9	13516	2647	50588952
Laryngeal dyspnoea	14.35	13.65	4	13521	150	50591449
Embedded device	14.03	13.65	9	13516	2828	50588771
Synovitis	13.77	13.65	8	13517	123857	50467742

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Victim of child abuse	123.63	17.48	30	6291	815	29567391
Respiratory depression	98.47	17.48	51	6270	13472	29554734
Drug hypersensitivity	96.04	17.48	94	6227	68312	29499894
Drug dependence	92.62	17.48	57	6264	20924	29547282
Treatment failure	86.61	17.48	68	6253	36871	29531335
Product prescribing error	72.18	17.48	46	6275	17930	29550276
Nightmare	68.87	17.48	38	6283	11379	29556827
Sedation	68.55	17.48	44	6277	17361	29550845
Epidural lipomatosis	63.37	17.48	17	6304	694	29567512
Nephrolithiasis	55.83	17.48	45	6276	25289	29542917
Juvenile idiopathic arthritis	52.07	17.48	17	6304	1377	29566829
Ulcerative keratitis	51.73	17.48	17	6304	1406	29566800
Anaphylactic reaction	48.46	17.48	43	6278	27530	29540676
Cataract	41.53	17.48	36	6285	22342	29545864
Asthma-chronic obstructive pulmonary disease overlap syndrome	35.79	17.48	11	6310	732	29567474
Burning feet syndrome	34.46	17.48	7	6314	81	29568125
Drug ineffective	30.30	17.48	155	6166	363015	29205191
Hyperhidrosis	29.59	17.48	51	6270	64489	29503717
Periorbital swelling	29.24	17.48	8	6313	352	29567854
Bronchial hyperreactivity	28.91	17.48	11	6310	1395	29566811
Intentional product misuse	28.39	17.48	36	6285	34625	29533581
Corneal thinning	26.01	17.48	6	6315	130	29568076
Obesity	24.91	17.48	19	6302	9844	29558362
Pulmonary function test abnormal	24.74	17.48	11	6310	2071	29566135
Child abuse	22.85	17.48	6	6315	225	29567981
Eye pain	22.20	17.48	19	6302	11576	29556630
Drug abuse	20.88	17.48	50	6271	79833	29488373
Non-infectious endophthalmitis	20.45	17.48	5	6316	140	29568066
Product used for unknown indication	20.19	17.48	6	6315	356	29567850
Corneal oedema	20.17	17.48	8	6313	1134	29567072
Aspirin-exacerbated respiratory disease	20.12	17.48	6	6315	360	29567846
Angioedema	19.83	17.48	29	6292	31886	29536320
Nausea	19.70	17.48	117	6204	289138	29279068
Urine analysis abnormal	19.67	17.48	9	6312	1811	29566395
Blood chromogranin A increased	18.78	17.48	5	6316	198	29568008
Neuromuscular block prolonged	18.73	17.48	6	6315	457	29567749
Urticaria	18.56	17.48	38	6283	54622	29513584
Eye swelling	18.26	17.48	15	6306	8642	29559564
Carcinoid crisis	18.01	17.48	5	6316	232	29567974

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	374.04	12.88	376	16056	237439	64244861
Victim of child abuse	117.45	12.88	30	16402	841	64481459
Respiratory depression	105.93	12.88	69	16363	23374	64458926
Punctate keratitis	103.07	12.88	27	16405	838	64481462
Corneal epithelium defect	79.78	12.88	21	16411	664	64481636
Spinal epidural haematoma	71.65	12.88	22	16410	1220	64481080
Anaphylactic reaction	68.60	12.88	86	16346	68578	64413722
Tendon disorder	68.25	12.88	33	16399	6299	64476001
Skin papilloma	64.93	12.88	30	16402	5173	64477127
Eye pain	64.62	12.88	58	16374	31567	64450733
Drug dependence	62.03	12.88	58	16374	33254	64449046
Nightmare	58.39	12.88	46	16386	20947	64461353
Anterior chamber cell	57.92	12.88	17	16415	807	64481493
Epidural lipomatosis	56.87	12.88	17	16415	860	64481440
Corneal oedema	54.38	12.88	21	16411	2322	64479978
Ulcerative keratitis	52.02	12.88	22	16410	3075	64479225
Injury	49.45	12.88	66	16366	55926	64426374
Aspirin-exacerbated respiratory disease	48.17	12.88	16	16416	1144	64481156
Nephrolithiasis	47.30	12.88	57	16375	43626	64438674
Renal infarct	43.42	12.88	18	16414	2393	64479907
Foreign body sensation in eyes	41.75	12.88	16	16416	1733	64480567
Uterine perforation	38.83	12.88	22	16410	5798	64476502
Eye irritation	38.29	12.88	32	16400	15824	64466476
Vision blurred	35.53	12.88	74	16358	90242	64392058
Product prescribing error	34.92	12.88	44	16388	35225	64447075
Sedation	33.76	12.88	47	16385	41415	64440885
Sleep disorder	33.56	12.88	57	16375	59652	64422648
Asthma-chronic obstructive pulmonary disease overlap syndrome	33.11	12.88	12	16420	1113	64481187
Juvenile idiopathic arthritis	32.36	12.88	17	16415	3862	64478438
Visual acuity reduced	32.00	12.88	37	16395	27104	64455196
Burning feet syndrome	30.51	12.88	7	16425	123	64482177
Ocular hyperaemia	30.44	12.88	33	16399	22531	64459769
Respiratory tract infection viral	29.37	12.88	14	16418	2589	64479711
Musculoskeletal disorder	29.22	12.88	29	16403	17877	64464423
Migraine	29.04	12.88	55	16377	62622	64419678
Corneal thinning	28.89	12.88	7	16425	157	64482143
Purpura fulminans	28.48	12.88	7	16425	167	64482133
Corneal opacity	27.93	12.88	10	16422	895	64481405
Concussion	27.86	12.88	20	16412	7918	64474382
Bronchial hyperreactivity	26.79	12.88	13	16419	2499	64479801
Emotional distress	26.62	12.88	39	16393	35999	64446301
Drug ineffective	26.00	12.88	327	16105	839920	63642380
Meniscus injury	25.73	12.88	17	16415	5890	64476410
Corneal abrasion	23.81	12.88	9	16423	939	64481361
Corneal disorder	23.17	12.88	11	16421	2016	64480284
Tracheal deviation	23.06	12.88	5	16427	67	64482233
Post-traumatic stress disorder	23.06	12.88	14	16418	4191	64478109
Intraocular pressure increased	22.67	12.88	18	16414	8284	64474016
Angioedema	22.40	12.88	49	16383	61772	64420528
Child abuse	22.10	12.88	6	16426	214	64482086
Immune thrombocytopenia	22.03	12.88	23	16409	15043	64467257
Urticaria	21.27	12.88	84	16348	147233	64335067
Pulmonary function test abnormal	21.22	12.88	12	16420	3152	64479148
Illness	21.13	12.88	27	16405	21911	64460389
Myelomalacia	20.20	12.88	5	16427	123	64482177
Death	20.04	12.88	60	16372	482645	63999655
Renal ischaemia	19.22	12.88	8	16424	1075	64481225
Phrenic nerve paralysis	17.34	12.88	5	16427	223	64482077
Drug abuse	17.15	12.88	73	16359	132301	64349999
Hyperhidrosis	17.05	12.88	70	16362	124850	64357450
Sinusitis	17.03	12.88	78	16354	145850	64336450
Ischaemic cardiomyopathy	16.92	12.88	14	16418	6824	64475476
Neuromuscular block prolonged	16.61	12.88	7	16425	970	64481330
Procedural pain	16.40	12.88	20	16412	15488	64466812
Eye swelling	16.29	12.88	24	16408	22257	64460043
Photophobia	16.21	12.88	21	16411	17272	64465028
Non-infectious endophthalmitis	15.90	12.88	5	16427	300	64482000
Condition aggravated	15.58	12.88	154	16278	372272	64110028
Asymptomatic bacteriuria	15.57	12.88	5	16427	321	64481979
Interstitial lung disease	15.57	12.88	3	16429	97729	64384571
Sickle cell anaemia with crisis	15.51	12.88	12	16420	5320	64476980
Corneal perforation	15.41	12.88	6	16426	678	64481622
Renal papillary necrosis	15.03	12.88	5	16427	359	64481941
Periorbital swelling	15.02	12.88	8	16424	1868	64480432
Abdominal pain	14.97	12.88	133	16299	312242	64170058
Heparin-induced thrombocytopenia test positive	14.97	12.88	4	16428	134	64482166
Blood chromogranin A increased	14.76	12.88	5	16427	380	64481920
Embedded device	14.67	12.88	9	16423	2743	64479557
Torsade de pointes	14.61	12.88	20	16412	17343	64464957
Fibrosis	14.54	12.88	11	16421	4717	64477583
Eye pruritus	14.49	12.88	17	16415	12642	64469658
Product used for unknown indication	14.29	12.88	6	16426	824	64481476
Anxiety	14.01	12.88	94	16338	202555	64279745
Carcinoid crisis	13.95	12.88	5	16427	449	64481851
Diarrhoea	13.31	12.88	119	16313	722585	63759715
Persistent corneal epithelial defect	13.22	12.88	3	16429	50	64482250
Lower respiratory tract infection	12.93	12.88	4	16428	94610	64387690

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AB15	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances
ATC	S01BC05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
ATC	S01FB51	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Sympathomimetics excl. antiglaucoma preparations
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50629	COX-2 inhibitor
CHEBI has role	CHEBI:50630	COX-1 inhibitor
MeSH PA	D000700	Analgesics
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug
FDA EPC	N0000175939	Cyclooxygenase Inhibitor
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Severe pain	indication	76948002
Allergic conjunctivitis	indication	473460002	DOID:11204
Acute postoperative pain	indication	107401000119105
Postoperative Ocular Pain	indication
Post-Op Ocular Inflammation	indication
Post-Op Photophobia	indication
Renal colic	off-label use	7093002
Peptic ulcer	contraindication	13200003	DOID:750
Disorder of cornea	contraindication	15250008	DOID:10124
Acute gastric ulcer with perforation	contraindication	19850005
Myocardial infarction	contraindication	22298006	DOID:5844
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Tear film insufficiency	contraindication	46152009
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Corneal erosion	contraindication	50792001
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Rheumatoid arthritis	contraindication	69896004	DOID:7148
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Hemophilia	contraindication	90935002
Corneal degeneration	contraindication	111521006	DOID:1237
Perioperative care	contraindication	133897009
Asthma	contraindication	195967001	DOID:2841
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Cerebral hemorrhage	contraindication	274100004
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Smokes tobacco daily	contraindication	449868002
Preoperative Pain Management	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.47	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.3% BASE;EQ 1% BASE	OMIDRIA	RAYNER SURGICAL	N205388	May 30, 2014	RX	SOLUTION	IRRIGATION	8173707	July 30, 2023	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
EQ 0.3% BASE;EQ 1% BASE	OMIDRIA	RAYNER SURGICAL	N205388	May 30, 2014	RX	SOLUTION	IRRIGATION	9278101	July 30, 2023	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8207215	May 28, 2024	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8377982	May 28, 2024	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8541463	May 28, 2024	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8906950	May 28, 2024	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8946281	May 28, 2024	A METHOD OF TREATING OCULAR PAIN
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	9216167	May 28, 2024	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
0.4%	ACULAR LS	ALLERGAN	N021528	May 30, 2003	RX	SOLUTION/DROPS	OPHTHALMIC	8008338	May 24, 2027	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	6.90	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	9.72	WOMBAT-PK	CHEMBL
Serine/threonine-protein kinase PAK 1	Kinase	Q13153	PAK1_HUMAN		IC50	4.44	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	4.94	CHEMBL
Aldose reductase	Enzyme		ALDR_RAT		IC50	5.21	DRUG MATRIX
Prostaglandin-H2 D-isomerase	Enzyme		PTGDS_MOUSE		IC50	6.64	CHEMBL

External reference:

ID	Source
4028637	VUID
N0000178380	NUI
D00813	KEGG_DRUG
74103-07-4	SECONDARY_CAS_RN
4019510	VANDF
4028637	VANDF
C0073631	UMLSCUI
CHEBI:6129	CHEBI
KTR	PDB_CHEM_ID
CHEMBL469	ChEMBL_ID
CHEMBL1201124	ChEMBL_ID
DB00465	DRUGBANK_ID
D020910	MESH_DESCRIPTOR_UI
3826	PUBCHEM_CID
6661	IUPHAR_LIGAND_ID
5558	INN_ID
YZI5105V0L	UNII
28200	RXNORM
30341	MMSL
39892	MMSL
4947	MMSL
9780	MMSL
d00273	MMSL
003539	NDDF
004812	NDDF
108512006	SNOMEDCT_US
108513001	SNOMEDCT_US
372501008	SNOMEDCT_US
D020911	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acular	HUMAN PRESCRIPTION DRUG LABEL	1	0023-2181	SOLUTION/ DROPS	5 mg	OPHTHALMIC	NDA	23 sections
ACUVAIL	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3507	SOLUTION/ DROPS	4.50 mg	OPHTHALMIC	NDA	23 sections
ACULAR LS	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9277	SOLUTION/ DROPS	4 mg	OPHTHALMIC	NDA	22 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0314	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0314	TABLET, FILM COATED	10 mg	ORAL	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0069	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0072	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	27 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0076	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	27 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1134	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9883	INJECTION, SOLUTION	30 mg	INTRAVENOUS	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9884	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	14 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9952	INJECTION, SOLUTION	15 mg	INTRAVENOUS	ANDA	14 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3793	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3793	INJECTION, SOLUTION	15 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3795	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3795	INJECTION, SOLUTION	30 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3796	INJECTION, SOLUTION	60 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3796	INJECTION, SOLUTION	60 mg	INTRAMUSCULAR	ANDA	15 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0487-6232	INJECTION	30 mg	INTRAMUSCULAR	ANDA	16 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6041	INJECTION	15 mg	INTRAMUSCULAR	ANDA	17 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6042	INJECTION	30 mg	INTRAMUSCULAR	ANDA	17 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6043	INJECTION	30 mg	INTRAMUSCULAR	ANDA	17 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-222	TABLET, FILM COATED	10 mg	ORAL	ANDA	29 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	12634-809	TABLET	10 mg	ORAL	ANDA	13 sections
ACULAR	HUMAN PRESCRIPTION DRUG LABEL	1	16590-002	SOLUTION/ DROPS	5 mg	OPHTHALMIC	NDA	20 sections
KETOROLAC	HUMAN PRESCRIPTION DRUG LABEL	1	16590-138	TABLET, FILM COATED	10 mg	ORAL	ANDA	15 sections
KETOROLAC TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-376	SOLUTION	5 mg	OPHTHALMIC	ANDA	18 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-207	SOLUTION/ DROPS	4.50 mg	OPHTHALMIC	ANDA	24 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-208	SOLUTION	4 mg	OPHTHALMIC	ANDA	22 sections
Ketorolac Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-209	SOLUTION	5 mg	OPHTHALMIC	ANDA	25 sections